PMV Pharmaceuticals
Clinical-stage precision oncology company developing selective small-molecule therapies that restore the tumor-suppressing function of mutant p53 proteins. The organization pursues a tumor-agnostic approach focused on p53 hotspot mutations, supporting programs from discovery and IND-enabling preclinical studies through early-phase clinical trials and commercial launch readiness.
Industries
Nr. of Employees
small (1-50)
PMV Pharmaceuticals
Patents
Products
Investigational oral small-molecule p53 Y220C reactivator (pivotal candidate)
Orally administered investigational small molecule designed to bind the structural crevice created by the p53 Y220C mutation and stabilize the mutant protein to restore DNA-binding and tumor suppressor function; under clinical evaluation for advanced solid tumors harboring the Y220C mutation.
Investigational oral small-molecule p53 Y220C reactivator (pivotal candidate)
Orally administered investigational small molecule designed to bind the structural crevice created by the p53 Y220C mutation and stabilize the mutant protein to restore DNA-binding and tumor suppressor function; under clinical evaluation for advanced solid tumors harboring the Y220C mutation.
Services
Sponsorship and operational management of early-phase multicenter clinical trials for biomarker-defined oncology indications.
Case-by-case evaluation of requests for investigational product outside of clinical trials, including physician-led inquiries, regulatory coordination and ethical review.
Advisory board management, medical education, field-based scientific exchange and MSL support to investigators and pathologists.
Sponsorship and operational management of early-phase multicenter clinical trials for biomarker-defined oncology indications.
Case-by-case evaluation of requests for investigational product outside of clinical trials, including physician-led inquiries, regulatory coordination and ethical review.
Advisory board management, medical education, field-based scientific exchange and MSL support to investigators and pathologists.
Expertise Areas
- Precision oncology targeting TP53 mutations
- Small-molecule drug discovery and medicinal chemistry
- Early-phase clinical development (Phase 1/2)
- Regulatory strategy and IND-enabling packages
Key Technologies
- Small-molecule drug discovery
- High-throughput biological screening
- Medicinal chemistry
- ADME/PK and pharmacology assays
News & Updates
Board appointment announced on October 5, 2026.
Executive appointment announced on September 8, 2026.
Public financing announced on August 31, 2026.
Board appointment announced on October 5, 2026.
Executive appointment announced on September 8, 2026.
Public financing announced on August 31, 2026.